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Abstract
Copy number variations (CNVs) are an important cause of ASD and those located at 15q11-q13, 16p11.2 and 22q13 have
been reported as the most frequent. These CNVs exhibit variable clinical expressivity and those at 15q11-q13 and 16p11.2
also show incomplete penetrance. In the present work, through multiplex ligation-dependent probe amplification (MLPA)
analysis of 531 ethnically admixed ASD-affected Brazilian individuals, we found that the combined prevalence of the 15q11-
q13, 16p11.2 and 22q13 CNVs is 2.1% (11/531). Parental origin could be determined in 8 of the affected individuals, and
revealed that 4 of the CNVs represent de novo events. Based on CNV prediction analysis from genome-wide SNP arrays, the
size of those CNVs ranged from 206 kb to 2.27 Mb and those at 15q11-q13 were limited to the 15q13.3 region. In addition,
this analysis also revealed 6 additional CNVs in 5 out of 11 affected individuals. Finally, we observed that the combined
prevalence of CNVs at 15q13.3 and 22q13 in ASD-affected individuals with epilepsy (6.4%) was higher than that in ASD-
affected individuals without epilepsy (1.3%; p,0.014). Therefore, our data show that the prevalence of CNVs at 15q13.3,
16p11.2 and 22q13 in Brazilian ASD-affected individuals is comparable to that estimated for ASD-affected individuals of pure
or predominant European ancestry. Also, it suggests that the likelihood of a greater number of positive MLPA results might
be found for the 15q13.3 and 22q13 regions by prioritizing ASD-affected individuals with epilepsy.
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Introduction
Autism Spectrum Disorder (ASD) is a complex genetic disorder
characterized by impaired social interaction and communication,
and restricted, repetitive and stereotyped behavior patterns. ASD
affects about 1% of the world population [1–3] and it occurs four
times more commonly in males than in females [4]. In Brazil, a
lower prevalence of ASD (0.27%) has been estimated, which was
attributed to misdiagnosis [5]. In addition to the core symptoms,
over 60% of the ASD-affected individuals can present other
clinical conditions, such as epilepsy (,30%), gastrointestinal
problems (9–70%), attention deficit and hyperactivity disorder –
ADHD – (,30%) and sleep disturbance (,50%) [6–8].
Genome-wide screenings for copy number variations (CNVs)
have revealed their occurrence in 10 to 20% of ASD individuals
[9–12], in which the great majority of CNVs is usually rare and
private. Exceptions to this rule are CNVs at 15q11-q13, 16p11.2
and 22q13, which, combined, have been found in roughly 3 to 5%
of ASD-affected individuals [10,13–15]. While most CNVs at
16p11.2 are about 600 kb [14], CNV sizes in the other two regions
vary widely. The 15q11-q13 region is particularly complex, with
five breakpoint clusters (BP1-BP5) that define chromosome
segments more prone to genomic rearrangements. Of these, the
most recurrent chromosomal abnormality among ASD-affected
individuals is a 15q11-q13 duplication (between BP2 and BP3, and
about 4.95 Mb) and CNVs at 15q13.2-q13.3 (between BP4 and
BP5 and ranging in size from 500kb to 2 Mb) [16–19]. The size of
the 22q13 CNVs ranges from 100 kb to 9 Mb and always involves
SHANK3 [20,21].
CNVs at 15q11-q13, 16p11.2 and 22q13 have also been
associated with other neurological conditions, such as epilepsy,
schizophrenia and ADHD [22–26]. Apart from the variable
clinical expressivity, these CNVs may exhibit incomplete pene-
trance [11,23,27]. The mechanism underlying the incomplete
penetrance and the variable expressivity is not fully understood
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and it seems to depend on multiple hits [28]. Furthermore, the
prevalence of these CNVs in distinct ASD subgroups (for instance,
in ASD-affected individuals with epilepsy as compared to those
without epilepsy) is unknown. Establishing clinical criteria to
increase the likelihood of positive results for these alterations is
important to prioritize genetic testing resources.
Whole-genome screening of CNVs in populations around the
world have shown that their frequencies vary according to the
ethnic background, allowing the distinction of populations of
European, African and Asian ancestries [29,30]. Studies of CNVs
at 15q11-q13, 16p11.2 and 22q13 have mostly been conducted in
populations of pure or predominant European ancestry. It is not
known whether they are also prevalent among ASD-affected
individuals in populations of other ancestries, such as the Brazilian
population, which is tri-hybrid, with important African and
Amerindian contributions in addition to the European ancestry
[31].
Thus, we conducted the present study to estimate the combined
frequency of CNVs at 15q11-q13, 16p11.2 and 22q13 within a
group of 531 Brazilian ASD-affected individuals, and we also
sought to determine the frequency of CNVs in those regions by
taking into account the epileptic and non-epileptic subgroups.
Finally, we aimed at investigating whether the individuals with
CNVs at the 15q11–13, 16p11.2 and 22q13 regions harbor
additional CNVs, through a genome-wide SNP-array analysis.
Materials and Methods
Subjects
This study was approved by the Ethics Committee of the
Instituto de Biociencias (IB) – Universidade de Sao Paulo (USP).
Written informed consent was obtained from all patients’
caregivers upon receiving information about the study.
Five hundred and thirty one Brazilian ASD-affected individuals
were recruited for this study and ascertained at the ‘‘Centro de
Pesquisa sobre o Genoma Humano e Ce´lulas Tronco’’ (CEGH-
Cel), IB-USP, following previously standardized criteria [32–34],
which included a detailed anamnesis – pregnancy history,
development history, age at onset, and weight, height and head
circumference measurements – and a pedigree analysis. All
probands were diagnosed according to Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria by
psychiatrists from Instituto de Psiquiatria, Hospital das Clinicas -
Universidade de Sao Paulo (IPq-USP). Whenever possible, an
interview based on Autism Diagnostic Interview-Revised (ADI-R)
and Childhood-Autism Rating Scale (CARS) evaluation was
applied, as previously reported [32]. Epilepsy diagnosis was based
on the occurrence of at least two unprovoked seizure episodes
occurring more than 24 hours apart. Whenever possible,
additional neurological and laboratorial tests were used to
complement the diagnosis.
Blood samples from probands and parents were obtained for
genomic DNA isolation, which was performed using the Autopure
LS automated workstation, following manufacturer’s procedures
(Gentra Systems, Minneapolis, US). All the affected boys tested
negative for Fragile X Syndrome [35].
Multiplex Ligation-dependent Probe Amplification
(MLPA) analysis
MLPA probe sets targeting the chromosomal regions 15q11-
q13, 16p11.2 and 22q13, SALSA MLPA kits P343-B1 and P343-
C1 that contain 52 probes (9 control probes, 3 covering
chr22:51,115,059–51,160,754, 11 covering chr16:28,997,152–
30,365,260, and 29 covering chr15:25,297,217–32,988,875). They
were purchased from MRC-Holland (Amsterdam, Netherlands)
and used according to the manufacturer’s protocol. The ampli-
fication products were identified and quantified by capillary
electrophoresis on an ABI 3730 DNA analyzer (Applied Biosys-
tems, Forster City, CA, US). The data were analyzed using
GeneMarker software v1.95 (SoftGenetics, State College, PA, US).
Threshold values for the peak height ratio were set at 0.75 and
1.3 for deletions and duplications, respectively.
Microsatellite genotyping
Seven microsatellite markers spanning the 15q11-q13 region
were genotyped to identify the parental origin of the duplication of
patient 2. The markers D15S1002, D15S1007 and D15S1012,
ABI PRISM Linkage Mapping Set version 2.0 (Applied Biosys-
tems, Forster City, CA, US) were genotyped following the
manufacturer’s protocol. The other primer sequence pairs,
D15S1043, D15S976, D15S1031 and D15S1010, were obtained
from the UCSC human genome browser (http://genome.ucsc.
edu/cgi-bin/hgGateway, Feb 2009 GRCh37/hg19) and a M13
tail was added to the 59-end of each forward primer [36].
Microsatellite genotyping was performed by means of an ABI
DNA Analyzer (Applied Biosystems, Forster City, CA, US).
Analysis of the results was performed with the GeneMarker v1.95
software (SoftGenetics, State College, PA, US).
CNV prediction analysis from genome-wide SNP arrays
CNV prediction analysis from genome-wide SNP arrays was
carried out using the Affymetrix platform (Affymetrix, Santa
Clara, CA, US): GeneChip Human Mapping 100K for ASD-
affected individuals 10, as described in [37], and 11, GeneChip
Human Mapping 500K Array Set for families of ASD-affected
individuals 2 and 3, and Genome-Wide Human SNP Array
6.0 for the remaining ASD-affected individuals and parents.
Protocols were performed according to the manufacturer’s
recommendations.
Data analyses were carried out with Affymetrix Genotyping
Console (Affymetrix, Santa Clara, CA, US) and PennCNV
(http://www.openbioinformatics.org/penncnv/), using the hg19
assembly (Genome Reference Consortium GRCh37). In both
analyses we used the default parameters recommended by the
manufacturers. A deletion or duplication was considered for
further analyses only when detected by both methods.
We considered a CNV as potentially pathogenic according to
two criteria: 1) they contained genes previously associated with
ASD and/or other neuropsychiatric and neurological disorders
(e.g. ADHD, global developmental delay, intellectual disability,
schizophrenia and epilepsy/seizure); and/or 2) they exhibited a
minimum overlap of 50% in length with CNVs previously
associated with these conditions. For this, we searched Simons
Foundation Autism Research Initiative (SFARI – https://gene.
sfari.org/autdb/Welcome.do) and Decipher (https://decipher.
sanger.ac.uk/) databases. Even though we analyzed, whenever
possible, if the CNVs had been inherited, we did not include this
information in the classification criteria. The CNVs considered as
potentially pathogenic were not found or occurred with a
frequency ,1% in the Database of Genomic Variants (DGV -
http://dgv.tcag.ca/dgv/app/home) [38,39].
Genome-wide SNP-array data are available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress) under accession numbers
E-MTAB-2818, E-MTAB-2819, E-MTAB-2820, E-MTAB-2821
and E-MTAB-2823.
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Ancestry Analysis
We analyzed the ancestry of 9 out of 11 Brazilian ASD-affected
individuals in whom high density genotyping (GeneChip Human
Mapping 500K Array Set and Genome-Wide Human SNP Array
6.0) was carried out. The PLINK tool set (http://pngu.mgh.
harvard.edu/purcell/plink/) [40] was used to merge the Brazilian
dataset with the Human Genome Diversity Project (HGDP) [41]
and HapMap project [42] datasets, and to select SNPs with a
missing call inferior to 1% (geno option to 0.01), which yielded
84,805 SNPs. Next, we used Ancestry Mapper package from R, to
produce AMids [43]. Admixture was used to produce ancestral
proportions for each individual [44]. The R statistical language
and environment [45] was used in most of the analysis, including
the visualization, plotting data and clustering algorithms. Python
was used to parse data and in some of the analysis.
Statistical Analysis
To assess the differences in CNV prevalence between the two
subgroups, ASD-affected individuals without (N = 453) and with
epilepsy (N = 78), we conducted two-tailed Fisher’s exact tests. P-
values below 0.05 were considered statistically significant.
Results
Through MLPA analysis, we identified CNVs at 15q11-q13
between BP4 and BP5 (15q13.3), and at 16p11.2 and 22q13,
respectively, in three (0.6%), five (0.9%), and three (0.6%) of the
531 (423 boys and 108 girls) Brazilian ASD–affected individuals
(Table 1; clinical characteristics in Table S1), which are ethnically
admixed (Table S2), with a combined prevalence of 2.1% (11/
531). In four of eight of those individuals, whose parents were
available for genetic testing, the CNVs were found to be de novo
(affected individuals 1, 6, 10 and 11). Among the other four
individuals (affected individuals 2, 3, 4 and 7), only one CNV was
maternally inherited (affected individual 7) (Table 1). The parents
of affected individual 2 are consanguineous and both are carriers
of the CNV at 15q13.3. The parents share a haplotype at this
region, suggesting a common origin of the 15q13.3 duplication.
Therefore, they probably inherited the CNV from their mothers,
who are sisters, while the proband inherited it from his father
(Figure 1A and 1B). None of the carrier parents reported
behavioral or neurological issues.
We conducted a CNV prediction analysis from genome-wide
SNP arrays in the 11 ASD-affected individuals in whom we
detected CNVs at 15q13.3, 16p11.2 and 22q13 regions to
determine their sizes as well as to verify whether another
potentially pathogenic CNV would be present. The 15q13.3,
16p11.2 and 22q13 CNVs sizes ranged from 206 kb to 2.27 Mb
(Table 1). It is worth noting that the two 15q13.3 duplications
were about 500 kb and included only the gene CHRNA7. Six
additional CNVs (3 duplications and 3 deletions) were identified in
5 of those affected individuals (1, 2, 4, 8 and 9), two of the CNVs in
individual 4 (Table 1). Four of these CNVs were inherited, while
the parents of the other two affected individuals were unavailable
for testing (Table 1). The 15q11.2 CNV in affected individual 2
was also present in both consanguineous parents and the maternal
copy was transmitted to the affected proband (Figure 1B).
Ancestry analysis was conducted in 9 out of 11 ASD-affected
individuals (Table S2), which showed that they have the three
main ancestral components commonly observed in the Brazilian
population.
Next, we evaluated if CNVs at 15q13.3, 16p11.2 and 22q13
occurred more often among ASD-affected individuals with
epilepsy. In our total sample, 78 (54 boys and 24 girls) of the
531 ASD-affected individuals had history of epilepsy (Table 2).
We observed that 6 of the 453 ASD-affected individuals without
epilepsy (1.3%) and 5 of the 78 ASD-affected individuals with
epilepsy (6.4%) had CNVs in one of these regions. These
frequencies were significantly different (p = 0.014; odds ratio = 5.1;
95% CI 1.19–20.55). CNVs at 15q13.3 and 22q13 among ASD-
affected individuals with epilepsy were responsible for these
differences (Table 2).
Discussion
In the Brazilian sample of ASD-affected patients, the frequen-
cies of CNVs at 15q13.3 (0.6%), 16p11.2 (0.9%), and 22q13
(0.6%) are consistent with those described in the literature [28,38–
42]. The Brazilian population is ethnically admixed, with around
56–62% of European contribution [31,46–48]. In ASD-affected
individuals positive for CNVs at 15q11-q13, 16p11.2 and 22q13,
we observed that the contribution of European ancestry varied
from 38 to 98%. This preliminary analysis suggests that the ethnic
admixture of our population is not influencing the occurrence of
these CNVs.
We identified both inherited and de novo CNVs at 15q11-q13
and 16p11.2, as previously described by other groups [49–52].
Indeed, it has been established that maternally and paternally
inherited as well as de novo 16p11.2 microdeletions and
microduplications contribute to the ASD phenotype [51,53–55].
Additionally, 15q13.3 deletions and maternally inherited duplica-
tions at 15q11-q13 have been implicated in an increased risk of
ASD [28,56,57]. However, the association between the 15q13.3
duplication, involving only CHRNA7, and neuropsychiatric
disorders is still controversial [24,49,58–60]. In our sample, the
two 15q13.3 duplications were inherited from the father, but both
maternally and paternally inherited 15q13.3 duplications have
been associated with the ASD phenotype [49,58]. Finally, our data
on the origin of the 22q13 deletions provide additional support to
the hypothesis that they usually represent de novo mutations
[21,61,62].
The size of the CNVs at 16p11.2 (600kb) and 15q13.3 (500kb or
1.6Mb), are within the range of those previously reported
[49,54,57], as expected due to the presence of segmental
duplications that flank these regions and mediate rearrangements
through non-allelic homologous recombination [49,54,63]. At
22q13 the size of the CNVs were quite variable, but always
included SHANK3. Loss-of-function mutations involving
SHANK3 cause Phelan-McDermid syndrome, an autosomal
dominant condition with full penetrance that presents ASD
among other clinical features [21,64]. In addition to the
aforementioned CNVs, five ASD-affected individuals also carried
at least another CNV with no correlation with the presence of
CNVs at 15q13.3, 16p11.2 or 22q13. All those additional CNVs
detected by the SNP-array platform overlap partially or
completely CNVs previously associated with ASD or other
neurological conditions [15,65–74]. Therefore, these additional
CNVs, which were found in nearly 50% of our affected
individuals, might contribute to the penetrance of the ASD
phenotype, in accordance with the two- or multiple hit hypotheses
for ASD, that is, these CNVs are not the cause ASD alone and
depend on the presence of at least a second mutation [58,75].
Further studies will be necessary for testing their effect and
specificity on the phenotype.
Our data suggest that CNVs at 15q13.3 and 22q13 are more
prevalent among ASD-affected individuals with epilepsy than
among those only with ASD. Indeed, it has been shown that
15q13.3 and 22q13 deletions represent strong genetic risk factors
CNVs at 15q, 16p and 22q in Individuals with ASD
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for ASD and epilepsy [76–79]. However, the contribution of
15q13.3 duplications, particularly those encompassing only
CHRNA7, to both phenotypes is still uncertain [19,49,58].
Although the 15q13.3 duplication has been implicated in several
psychiatric conditions [24,60,80], rare cases presented epilepsy as
well [49,81,82]. Within this context, ASD-affected individual 2
deserves special attention: while his 15q13.3 duplication was
paternally inherited, his parents, who do not have any history of
epilepsy, probably inherited the duplication from their mothers
(who are sibs). This individual also harbors a deletion at 15q11.2
(Table 1), which in turn was inherited from his mother, even
though both parents carry this 15q11.2 deletion (Figure 1). De
novo or inherited deletions at 15q11.2 have been associated with
both epilepsy and ASD, however the relative risk that this CNV
confers to ASD is low [70,83,84]. It is thus possible that CNVs
both at 15q11.2 and 15q13.3 are causative factors of ASD and/or
epilepsy, supporting the etiologic models that involve multiple
genetic alterations in ASD, since both alterations have incomplete
penetrance but have already been reported in ASD and other
neuropsychiatric diseases.
None of our ASD individuals with epilepsy carry a
16p11.2 CNV. Even though CNVs at 16p11.2 have been
associated with epilepsy, this finding is not unexpected, as the
phenotype of patients with these CNVs is extremely variable and
Figure 1. ASD-affected individual 2 pedigree and haplotypes. A) Pedigree of the ASD-affected individual. B) Haplotype analysis of SNPs and
microsatellite markers at 15q11-q13. ASD-affected individual – filled symbol; Carriers of 15q13.3 duplication and 15q11.2 deletion – symbols with a
black dot in the middle; individuals unavailable or not affected – empty symbols; non-available individuals – n.a. * Distance (in kilobases) from
anterior to posterior marker/dbSNP. The other microsatellite markers are not showed.
doi:10.1371/journal.pone.0107705.g001
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the overlap between ASD and epilepsy is not often observed
among them [55,85–88].
In summary, this work describes the combined prevalence of
CNVs at 15q13.3, 16p11.2 and 22q13 as 2.1% in Brazilian ASD-
affected individuals. CNVs at 15q13.3 and 22q13 were signifi-
cantly more frequent in ASD-affected individuals with epilepsy in
our sample; hence, these CNVs should be preferentially screened
in ASD-affected individuals if resources are limited. Other
potentially pathogenic CNVs were identified in 5 out of
11 ASD-affected individuals studied, thus highlighting the need
for understanding how those and other genetic alterations interact
to give rise to ASD and other clinical complications.
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